Ignite Creation Date:
2025-12-25 @ 2:07 AM
Ignite Modification Date:
2026-04-14 @ 12:04 AM
Study NCT ID:
NCT01769560
Status:
COMPLETED
Last Update Posted:
2015-07-22
First Post:
2013-01-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
Sponsor:
University of Michigan
Organization:
Study Overview
Official Title:
MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.
Detailed Description:
MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: